Inhibition of osteoclastogenic differentiation by Ikarisoside A in RAW 264.7 cells via JNK and NF-κB signaling pathways

Dihydrotestosterone Downregulates Bone Resorption Activity of Osteoclasts in Dose Dependent Manner: An in Vitro Model Using Raw 264.7 Cells

“…Moreover, in NFATc1 knock-out mice, defective osteoclast differentiation and osteopetrosis have been noted. NFATc1 plays an important role in osteoclast activation through the release of osteoclastogenesis-related genes such as TRAP and MMP-9 and the expression of these mediators is mainly responsible for the degradation of bone mineral and collagen matrices [12][13][14]. In the present study, we noticed that 5α-DHT exerted significant inhibitory effects on the expression of NFATc1 in vitro.…”

“…Upon activation, RAW 264.7 cells stimulate activation of an important transcription factor, nuclear factor of activated T-cells cytoplasmic 1 (NFATc1), for osteoclastogenesis [11]. As a master transcription factor of osteoclastogenesis, NFATc1 regulates diverse osteoclastogenesisrelated proteins such as TRAP, cathepsin-K and MMP-9 [12][13][14].…”

Gastrodin: An ancient Chinese herbal medicine as a source for anti-osteoporosis agents via reducing reactive oxygen species

“…Osteoclasts are derived from monocyte/macrophage lineages [52]. Mature osteoclasts are characterized by morphologic conversion into large multinucleated osteoclastic cells, as well as the expressions of specific markers, such as TRAP, CTSK and CTR [53][54][55][56]. Our results showed that gastrodin treatment reduced both number of osteoclasts and the mRNA expressions of osteoclast-specific genes, including NFATc1, TRAP, CTR and CTSK under oxidative status.…”

The genus Epimedium: An ethnopharmacological and phytochemical review

“…Ikarisoside A is a potent inhibitor of osteoclastogenesis in NF-B ligand-stimulated RAW 264.7 cells as well as in bone marrowderived macrophages. Ikarisoside A (2.5-20 M) decreased the expression of osteoclast-specific genes, such as matrix metalloproteinase 9, tartrate-resistant acid phosphatase, receptor activator of NF-B (RANK) and cathepsin K. These data indicate that ikarisoside A has potential use in the treatment of diseases involving abnormal bone lysis, such as osteoporosis, rheumatoid arthritis and periodontal bone erosion (Choi et al, 2010). Icariin at the concentrations of 100 and 50 mol/l significantly inhibited the formation of osteoclast-like cells in rabbit bone-marrow cells induced by 1,25-(OH) 2 D 3 .…”